Beate Schmöle-Thoma
7PUBLICATIONS
7CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (7)
Sort by Publication Date:
|Jun 13, 2020
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in patients with immunocompromising conditions: a review of available evidence.Erica Chilson, Daniel A Scott, Beate Schmoele-Thoma
|Jun 10, 2020
Diabetes mellitus as a vaccine-effect modifier: a review.Thomas Verstraeten, Mark A Fletcher, Jose A Suaya
|Jan 17, 2019
Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults.Beate Schmoele-Thoma, Martin van Cleeff, Richard N Greenberg
|Oct 11, 2018
Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial.Allison R Thompson, Nicola P Klein, H Jackson Downey
|Mar 16, 2018
Late onset of injection site reactions after vaccination with the 13-valent pneumococcal conjugate vaccine in adult study populations.Christine Juergens, James Trammel, Yasuko Shoji
|Nov 30, 2017
Pneumococcal conjugate vaccine use for the prevention of pneumococcal disease in adults <50 years of age.Raul E Isturiz, Cassandra Hall-Murray, John M McLaughlin
Pageof 2
